The epithelium-speci®c transcription factor, ERT/ESX/ ESE-1/ELF3, binds to the TGF-b RII promoter in a sequence speci®c manner and regulates its expression. In this study, we investigated whether ERT could regulate endogenous TGF-b RII expression in Hs578t breast cancer cells. Analyses of the Hs578t parental cell line revealed low RII mRNA expression and resistance to the growth inhibitory eects of TGF-b. Infection of this cell line with a retroviral construct expressing ERT induced higher levels of endogenous RII mRNA expression and protein expression relative to cells infected with chloramphenicol acetyltransferase (CATneo) as a control. Relative to control cells, the ERTneo-expressing Hs578t cells show approximately a 50% reduction in cell growth in the presence of exogenous TGF-b1, as well as a fourfold higher induction of activation in transient transfection assays using the 3TP-luciferase reporter construct. When transplanted into athymic mice, ERTexpressing Hs578t cells showed decreased and delayed tumorigenicity compared with control cells. This data strongly suggests that ERT plays an important role as a transcriptional activator of TGF-b RII expression, and that deregulated ERT expression may play a critical role in rendering Hs578t human breast cancer cells insensitive to TGF-b's growth inhibitory eects. Oncogene (2000) 19, 151 ± 154.
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Keywords: transcription factor; cancer; TGF-b; tumorigenicity TGF-b-mediated growth inhibition involves an intricate signaling pathway made up of cell surface receptors and intermediate signaling proteins (Roberts and Sporn, 1990; MassagueÂ et al., 1997; Heldin et al., 1997) . Of the major cell surface receptors, functional analyses have shown that only the type I and type II receptors (RI and RII, respectively) are necessary to facilitate signal transduction, which occurs via intrinsic serine threonine kinase activity (Lin et al., 1992; Wrana et al., 1994) . TGF-b signaling occurs when the TGF-b ligand binds to RII, which then recruits and subsequently transphosphorylates RI, thereby initiating the signal transduction cascade. Inactivation of these receptors or the intracellular machinery can render cells resistant to TGF-b's anti-proliferative eects, leading to unregulated cell growth and ultimately to carcinogenesis .
In the last few years, numerous studies have demonstrated a high correlation between defects in RII expression and TGF-b resistance in various cancer cells (Kadin et al., 1994; Park et al., 1994; Capocasale et al., 1995; Markowitz et al., 1995) . Moreover, some of these studies have identi®ed speci®c events and/or have proposed mechanisms that may be attributable to RII inactivation. Markowitz et al. (1995) have identi®ed mutations which frequently occur in cells with defective DNA repair in the poly(A) tract of the TGF-b RII, leading to premature termination of the receptor protein . We have also found a strong correlation between structural abnormalities in the TGF-b RII gene and the development of TGF-b resistance in a subset of human gastric cancer cell lines (Park et al., 1995) . The signi®cance of TGF-b RII as a tumor suppressor gene has been further strengthened by studies that have demonstrated that restoring wild type TGF-b RII into cell lines bearing these various RII mutations can reverse malignancy and restore TGF-b sensitivity in human gastric, colon, breast, and hepatoma cancer cells (Inagaki et al., 1993; Sun et al., 1994; Chang et al., 1997b) .
Despite the high frequency of RII mutation in TGFb resistant gastric cancer cells, we have identi®ed a subset of gastric cancer cell lines which bear undetectable levels of RII yet do not reveal any structural alterations, suggesting a dierent mechanism which may confer RII inactivation Markowitz and Roberts, 1996) . Transcriptional regulation of the RII gene has been shown to play an important role in modulating TGF-b responsiveness.
In a recent study, our laboratory cloned a novel transcription factor, ERT, which was shown to interact with purine rich sequences in the TGF-b RII promoter region. The isolation and sequencing of the clone ERT/ ESX/ESE-1/ELF3, which induced promoter activity, revealed it to be a member of the ets family of transcription factors (Chang et al., 1997a; Oettgen et al., 1997; Tymms et al., 1997; Choi et al., 1998) . Recently, we have demonstrated that most of the ets family members examined regulate expression of the TGF-b RII gene, suggesting that ets family members may be the major transcriptional factors involved in regulation of TGF-b RII gene expression (Choi et al., 1998) .
This study investigates the potential of ERT to induce endogenous RII expression in a TGF-b insensitive Hs578t human breast cancer cell line. Hs578t cells, shown previously to express low levels of TGF-b RII mRNA and low to undetectable levels of ERT, were infected with retroviral constructs to express the ERT and CAT genes. Stable clones were pooled after retroviral delivery of the MFG-ERTneo and MFG-CATneo expression constructs, which utilize the replication defective MFG vector (Ohashi et al., 1992) . Northern analysis revealed that the Hs578t ERTneo cells, which expressed high levels of ERT mRNA, consistently exhibited increased levels of TGFb RII mRNA relative to CATneo-expressing Hs578t cells ( Figure 1A) .
Cell-surface expression of TGF-b RII protein was increased as well in the ERTneo-expressing Hs578t cells. A receptor cross-linking assay using 125 I-labeled TGF-b was performed to determine whether increased TGF-b RII mRNA expression in ERT overexpressed clones translated into increased TGF-b RII protein expression. Hs578t ERTneo clones exhibit a signi®cant increase in TGF-b RII protein relative to control cells. Furthermore, Figure 1B shows that elevated TGF-b RII expression also increases cell surface expression of the TGF-b type I receptor, which supports the theory that TGF-b RII recruits TGF-b RI in ligand-receptorinduced signaling.
In order to assess the ecacy of ERT in restoring TGF-b's growth inhibitory eects on proliferating Hs578t cells, we compared cell proliferation in both ERTneo-and CATneo-expressing stable clones. Cells expressing ERTneo and CATneo were treated with 5 ng/ml of TGF-b1 and proliferation was assessed using a [ 3 H]thymidine incorporation assay (Figure 2A) . We found that cell growth in Hs578t CATneo cells actually increases in the presence of exogenous TGFb1, whereas the addition of TGF-b1 inhibits cell growth in Hs578t ERTneo cells by nearly 50%. This strongly suggests that low TGF-b RII expression, possibly due to low to undetectable expression of ERT, may confer TGF-b resistance in Hs578t cells, and also that the remaining TGF-b signaling machinery is intact.
In order to assess whether this intracellular mechanism was present and functional in MFG-ERTinfected cells, a luciferase reporter construct, 3TP-Lux, which contains multiple TGF-b responsive elements, was transiently transfected into both CATneo-and ERTneo-Hs578t cells. Exogenous TGF-b1 induced luciferase activity fourfold in ERTneo-Hs578t cells with no observable induction in control cells ( Figure  2B ).
Our previous study has shown that ERT shares a highly conserved DNA binding domain with the ets family of transcription factors (Macleod et al., 1992; Watson et al., 1992) . Ets proteins characteristically bind to the promoters/enhancers of a variety of cellular and viral genes in a sequence speci®c manner, notably to a purine-rich sequence known as the Ets Binding Site (EBS), which was also identi®ed in the PRE2 of the TGF-b RII promoter. Figure 3 illustrates the ability of both the CATneo-and ERTneo-Hs578t cells to induce transcriptional activation, represented by relative luciferase activity, when cotransfected with either a basic luciferase reporter (pGL2-basic) or the reporter linked to the TGF-b RII promoter (pTbRIIP, 71670/+36). The Hs578t ERTneo cell line confers a ®vefold increase in luciferase activity relative to the control, which clearly demonstrates that ERT can act through the TGF-b RII promoter in these breast cancer cells to induce transcription.
To test whether restoration of TGF-b signaling might render these cells less tumorigenic, exponentially growing CATneo-and ERTneo-expressing Hs578t cells were inoculated into athymic nude mice at a dose of 5610 6 cells/site, and the mice were monitored for progression of xenograft formation. The appearance of xenografts was signi®cantly delayed after inoculation of ERTneo Hs578t cells compared to that of CATneo Hs578t cells (Figure 4) , suggesting that ERT suppresses tumorigenicity. Moreover, when tumor burden was measured at day 25, the xenograft size of ERTneo Hs578t cells was less than 30% of that of CATneo Hs578t cells. Since it has been demonstrated that introduction of TGF-b RII suppresses tumorigenicity in some cancer cell lines (Sun et al., 1994; Chang et al., 1997b) , a decrease in tumorigenicity by (Choi et al., 1998) fragment was PCR ampli®ed, restrictiondigested, and puri®ed to be subcloned into the MFG vector (Ohashi et al., 1992 ). An IRES-NEO cassette was also subcloned into the construct to obtain stable transfectants. Generation of stable cell lines and the TGF-b RII receptor cross-linking assay were described previously (Chang et al., 1997) . (A) Northern blot analysis of ERT mRNA and TGF-b RII mRNA in the MFGERTneo-and MFG-CATneo-Hs578t cell lines. Total RNA (10 mg) was isolated from the ERT-transfected and CATtransfected (control) human breast cancer cell lines and analysed by Northern analysis using 32 P-labeled ERT and TGF-b RII probes (Choi et al., 1998; Lin et al., 1992) . Radiolabeled probes for GAPDH and 5S snRNA were used to control for loading. (B) Receptor protein cross-linking assay using iodinated TGF-b1. Receptor-ligand binding was performed with 100 pM 125 I-labeled TGF-b1 in the presence (lanes 2 and 4) or absence (lanes 1 and 3) of 100-fold molar excess of unlabeled TGF-b1. Bound proteins were cross-linked using 300 mM disuccinimidyl suberate, solubilized, and separated with gel electrophoresis. Assays were repeated three times, and a representative gel is shown. Levels of TGF-b type I and type II receptor were signi®cantly increased in the ERTneo-expressing Hs578t cell line compared with CATneo-expressing control cells
ERT may be, in part, due to enhanced TGF-b RII expression.
In this study, we demonstrate that overexpression of ERT, utilizing retroviral delivery techniques, enhances TGF-b RII expression and consequently restores TGFb sensitivity in Hs578t breast cancer cells. Analysis of parental Hs578t cells revealed low TGF-b RII expression and undetectable ERT expression. We hypothesized that TGF-b resistance in these cells might be directly associated with low receptor expression, that ERT could induce transcription of the TGF-b RII gene, and that the remaining signaling 5 cells/well in 6-well plates and transfected transiently with the promoter construct p3TP-lux, which contains multiple TGF-b responsive elements, using Lipofectin (Life Technologies, Inc.). After 12 h, complete media was added, and the cells were incubated for an additional 48 h in the presence or absence of 5 ng/ml TGF-b1. Luciferase activity was measured following lysate collection using an assay kit (Analytic Luminescence Lab) and a Dynatech Laboratories ML3000 luminometer. Activity was normalized on the basis of b-galactosidase expression from pSVb-galactosidase in all luciferase reporter experiments. All experiments were repeated at least three times, and similar results were obtained each time and CATneo (open circle) were inoculated s.c. into nude mice (n=10). The mice were maintained in a pathogen-free environment. Tumor volume was measured for 4 weeks. The tumor growth rate was determined by measuring the xenografts in three dimensions. Volume (V) was determined using the equation V=(L6W 2 )60.5, in which V=volume, L=length, and W=width. Values are the means+s.e.m. of established tumors machinery was intact. The ERTneo-expressing Hs578t cells exhibited a marked reduction in cell proliferation in response to exogenous TGF-b, whereas control CATneo-expressing Hs578t cells failed to show responsiveness, which suggests that increased endogenous TGF-b RII expression induced by ERT overexpression is sucient to confer TGF-b-mediated growth inhibition. Transient transfection studies, utilizing 3TP-lux as well as several other promoter constructs linked to the luciferase reporter, consistently showed signi®cant increases in luciferase expression, supporting our conclusions.
Interest in the ets family of transcription factors has risen over the past several years. Except for ERF and yan, all other ets members are transcriptional transactivators (Lai and Rubin, 1992; Macleod et al., 1992; Watson et al., 1992; Sgouras et al., 1995) , and can initiate transcription from a variety of cellular and viral promoter/enhancer elements (Macleod et al., 1992; Watson et al., 1992) . Ets proteins are tissue speci®c and bind DNA in a sequence speci®c manner, most notably to a motif known as the ETS Binding Site (EBS), which is a purine rich core sequence typically represented by GGAA sequences. The identi®cation of EBS in a wide spectrum of promoter genes has implicated Ets transcription factor involvement in gene regulation during numerous biological processes, including growth control, transformation, Tcell activation, and organism development (Macleod et al., 1992; Watson et al., 1992) . Recent studies have implicated members of the ets family of transcription factors in pathogenic mechanisms that lead to numerous malignancies. We previously identi®ed multiple EBSs in the TGF-b RII promoter, which suggests the functional importance of these sites in the transcriptional regulation of the RII gene (Choi et al., 1998) .
TGF-b-mediated signaling and growth inhibition requires normal expression and function of the TGFb type II receptor. Altered TGF-b RII expression has been highly correlated with TGF-b resistance in many human malignancies including colon, gastric, and breast carcinoma. The identi®cation of TGF-b resistant cell lines with lowered TGF-b RII mRNA expression despite evidence of a normal gene suggests an important role for transcriptional regulation in modulating proper TGF-b responsiveness.
